The Patent Finder

PharmaIN Corporation

15 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

10
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 28, 2027
    The maintenance fee for Composition for long-acting peptide analogs (US 9,090,664) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same (US 10,624,966) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,507,248Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,562,111Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,737,615Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,518,876Composition for long-acting peptide analogs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,090,664Composition for long-acting peptide analogs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,657,078Composition for long-acting peptide analogs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,563,527Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,960,336Composition for long-acting peptide analogs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,999,930Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
In force
 · Medium confidence
In forceMedium confidence
US 10,624,966Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 8 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited